Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Immune checkpoint inhibitors (ICIs) have been used to successfully treat primary liver cancer (PLC); however, identifying modifiable patient factors associated with therapeutic benefits is challenging. |